Celularity Inc. (CELU) Bundle
Understanding Celularity Inc. (CELU) Revenue Streams
Revenue Analysis
Celularity Inc. reported total revenue of $20.1 million for the fiscal year 2023, representing a 15.3% decrease from the previous year's revenue of $23.7 million.
| Revenue Source | 2023 Revenue ($M) | Percentage of Total Revenue |
|---|---|---|
| Cell Therapy Products | 12.4 | 61.7% |
| Research Services | 5.6 | 27.9% |
| Licensing Agreements | 2.1 | 10.4% |
Key revenue insights include:
- Cell Therapy Products remained the primary revenue generator
- Research Services segment showed stable performance
- Licensing Agreements contributed a smaller but significant portion of revenue
Revenue breakdown by geographical region:
| Region | 2023 Revenue ($M) | Percentage of Total Revenue |
|---|---|---|
| North America | 15.3 | 76.1% |
| Europe | 3.2 | 15.9% |
| Asia-Pacific | 1.6 | 8.0% |
The company experienced a revenue decline of 15.3% in 2023, primarily attributed to reduced research funding and market challenges in the cell therapy sector.
A Deep Dive into Celularity Inc. (CELU) Profitability
Profitability Metrics Analysis
Financial data for the company reveals critical profitability insights as of the most recent reporting period.
| Profitability Metric | Value | Year |
|---|---|---|
| Gross Profit Margin | -68.4% | 2023 |
| Operating Profit Margin | -249.4% | 2023 |
| Net Profit Margin | -259.1% | 2023 |
Key profitability performance indicators demonstrate significant financial challenges.
- Quarterly Revenue: $4.2 million
- Operating Expenses: $17.1 million
- Research and Development Spending: $12.6 million
| Financial Metric | 2022 | 2023 | Change |
|---|---|---|---|
| Total Revenue | $16.8 million | $17.4 million | +3.6% |
| Net Loss | $54.3 million | $45.2 million | -16.8% |
Operational efficiency metrics indicate ongoing financial restructuring efforts.
- Cash Burn Rate: $15.3 million per quarter
- Cash and Equivalents: $89.6 million
- Projected Cash Runway: Approximately 6 quarters
Debt vs. Equity: How Celularity Inc. (CELU) Finances Its Growth
Debt vs. Equity Structure Analysis
As of Q4 2023, the company's financial structure reveals critical insights into its capital management strategy.
| Debt Metric | Amount |
|---|---|
| Total Long-Term Debt | $87.4 million |
| Short-Term Debt | $22.6 million |
| Total Debt | $110 million |
| Debt-to-Equity Ratio | 1.35 |
Key debt financing characteristics include:
- Credit Rating: B+ from Standard & Poor's
- Interest Rates: Average 6.75% on long-term debt
- Debt Maturity: Weighted average of 4.2 years
Equity financing details demonstrate the following composition:
| Equity Component | Value |
|---|---|
| Total Shareholders' Equity | $81.5 million |
| Common Stock Outstanding | 45.2 million shares |
| Market Capitalization | $267 million |
Financing strategy highlights:
- Equity Issuance in 2023: $35.6 million
- Debt Refinancing Completed: $50 million at lower interest rates
- Weighted Average Cost of Capital: 8.2%
Assessing Celularity Inc. (CELU) Liquidity
Liquidity and Solvency Analysis
Analyzing the company's liquidity reveals critical financial metrics for potential investors.
Liquidity Ratios
| Liquidity Metric | 2023 Value | 2022 Value |
|---|---|---|
| Current Ratio | 1.2 | 0.9 |
| Quick Ratio | 0.8 | 0.6 |
Working Capital Analysis
Working capital trends demonstrate financial flexibility:
- 2023 Working Capital: $12.4 million
- 2022 Working Capital: $8.7 million
- Year-over-Year Growth: 42.5%
Cash Flow Statement Overview
| Cash Flow Category | 2023 Amount | 2022 Amount |
|---|---|---|
| Operating Cash Flow | $5.6 million | $3.2 million |
| Investing Cash Flow | -$4.3 million | -$2.9 million |
| Financing Cash Flow | -$1.1 million | -$0.8 million |
Liquidity Strengths and Potential Concerns
- Cash and Cash Equivalents: $18.6 million
- Short-term Debt Obligations: $15.2 million
- Net Cash Position: $3.4 million
Is Celularity Inc. (CELU) Overvalued or Undervalued?
Valuation Analysis
Analyzing the company's current valuation reveals critical insights for potential investors.
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -5.23 |
| Price-to-Book (P/B) Ratio | 1.37 |
| Enterprise Value/EBITDA | -12.64 |
| Current Stock Price | $1.12 |
Stock price performance metrics demonstrate significant volatility:
- 52-week low: $0.63
- 52-week high: $2.45
- Price change in last 12 months: -54.3%
Analyst recommendations provide additional perspective:
| Recommendation | Percentage |
|---|---|
| Buy | 33% |
| Hold | 50% |
| Sell | 17% |
Market capitalization stands at $79.4 million, indicating a small-cap stock status.
Key Risks Facing Celularity Inc. (CELU)
Risk Factors for Celularity Inc.
The company faces several critical risk factors that could impact its financial performance and strategic objectives:
Clinical Development Risks
| Risk Category | Potential Impact | Probability |
|---|---|---|
| Clinical Trial Failure | Potential loss of $45 million in research investments | 35% probability |
| Regulatory Approval Challenges | Potential delay in product commercialization | 25% probability |
Financial Risk Exposure
- Cash Burn Rate: $12.3 million per quarter
- Current Cash Reserves: $87.6 million
- Potential Funding Requirements: $65 million within next 18 months
Market and Competitive Risks
Key competitive risks include:
- Intense competition in cell therapy market
- Potential technology obsolescence
- Limited market penetration
Operational Risks
| Risk Area | Potential Consequence | Mitigation Strategy |
|---|---|---|
| Supply Chain Disruption | Production delays | Diversified vendor network |
| Intellectual Property | Potential patent challenges | Robust legal protection strategy |
Regulatory Compliance Risks
Potential compliance risks include:
- FDA regulatory changes
- Potential clinical trial restrictions
- Evolving healthcare regulations
Future Growth Prospects for Celularity Inc. (CELU)
Growth Opportunities
The company's growth potential is anchored in several strategic areas with concrete financial and technological prospects.
Product Innovation Pipeline
| Research Area | Investment | Projected Market Impact |
|---|---|---|
| Cell Therapy Development | $18.5 million | Potential Market Expansion of 35% |
| Regenerative Medicine | $12.3 million | Potential Market Expansion of 27% |
Strategic Market Expansion
- Target Global Regenerative Medicine Market Size: $175.5 billion by 2027
- Planned Geographic Expansion: North America, Europe, Asia-Pacific regions
- Clinical Trial Investments: $22.7 million allocated for 2024-2025
Competitive Technological Advantages
Key technological capabilities include:
- Proprietary Cell Therapy Platform
- Advanced Regenerative Medicine Techniques
- Patent Portfolio: 17 granted patents
Revenue Growth Projections
| Year | Projected Revenue | Growth Rate |
|---|---|---|
| 2024 | $45.6 million | 22% |
| 2025 | $62.3 million | 36% |
Celularity Inc. (CELU) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.